{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T02:11:34Z","timestamp":1784513494220,"version":"3.55.0"},"reference-count":99,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T00:00:00Z","timestamp":1643932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>It is unclear whether inflammatory bowel diseases (IBDs) affect the phenotype and severity of co-occurring immune-mediated inflammatory diseases (IMIDs). We aimed to investigate the characteristics of IMIDs in relation to co-occurring IBD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a systematic review of Medline and EMBASE databases from inception to September 2020. We identified studies reporting the phenotype, severity, or disease course of IMIDs among patients with or without co-occurring IBD. A meta-analysis was conducted using random effects models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The electronic search yielded 13\u00a0220 studies that we narrowed down to 73 eligible studies for full-text review, including 42 on primary sclerosing cholangitis, 12 on axial spondyloarthropathies, and 8 studies on psoriasis. In primary sclerosing cholangitis, IBD was associated with less frequent involvement of extrahepatic bile ducts (risk ratio [RR], 0.50; 95% confidence interval [CI], 0.33-0.75), longer liver transplantation\u2013free survival (hazard ratio, 0.70; 95% CI, 0.60-0.82), and no increased risk of cholangiocarcinoma (RR, 0.88; 95% CI, 0.59-1.31). Patients with axial spondyloarthropathies and co-occurring IBD were characterized by an increased risk of dactylitis (RR, 2.06; 95% CI, 1.24-3.42), a lower Bath Ankylosing Spondylitis Radiology Index (mean difference [MD] = -2.28; 95% CI, -3.26 to -1.30), and better Schober\u2019s test results (MD = 1.07; 95% CI, 0.64-1.49). Psoriasis and co-occurring IBD was associated with reduced disease severity (RR, 1.41; 95% CI, 1.02-1.96) and less frequent presentation in nails (RR, 0.14; 95% CI, 0.05-0.42), with no apparent impact on psoriatic arthritis (RR, 0.94; 95% CI, 0.27-3.31).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This systematic review with meta-analysis found IBD is associated with a distinct disease phenotype among the IMIDs investigated. Our findings emphasize the importance of multidisciplinary approaches to patients with co-occurring IMIDs and IBD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ibd\/izac003","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:21:01Z","timestamp":1644366061000},"page":"1756-1765","source":"Crossref","is-referenced-by-count":9,"title":["Inflammatory Bowel Diseases Affect the Phenotype and Disease Course of Coexisting Immune-Mediated Inflammatory Diseases: A Systematic Review With Meta-Analysis"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0323-7030","authenticated-orcid":false,"given":"Mohamed","family":"Attauabi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Herlev Hospital, University of Copenhagen, Copenhagen , Denmark"},{"name":"Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Hvidovre Hospital, University of Copenhagen , Hvidovre , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9140-9706","authenticated-orcid":false,"given":"Mads Damsgaard","family":"Wewer","sequence":"additional","affiliation":[{"name":"Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Hvidovre Hospital, University of Copenhagen , Hvidovre , Denmark"},{"name":"Gastrounit, Medical Section, Hvidovre Hospital , Hvidovre , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8419-2104","authenticated-orcid":false,"given":"Flemming","family":"Bendtsen","sequence":"additional","affiliation":[{"name":"Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Hvidovre Hospital, University of Copenhagen , Hvidovre , Denmark"},{"name":"Gastrounit, Medical Section, Hvidovre Hospital , Hvidovre , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3230-7966","authenticated-orcid":false,"given":"Jakob Benedict","family":"Seidelin","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Herlev Hospital, University of Copenhagen, Copenhagen , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3312-5139","authenticated-orcid":false,"given":"Johan","family":"Burisch","sequence":"additional","affiliation":[{"name":"Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, Hvidovre Hospital, University of Copenhagen , Hvidovre , Denmark"},{"name":"Gastrounit, Medical Section, Hvidovre Hospital , Hvidovre , Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,4]]},"reference":[{"key":"2023112213075425700_CIT0001","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1053\/j.gastro.2011.10.001","article-title":"Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review.","volume":"142","author":"Molodecky","year":"2012","journal-title":"Gastroenterology"},{"key":"2023112213075425700_CIT0002","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1136\/gutjnl-2011-301397","article-title":"Hospitalisations and surgery in Crohn\u2019s disease.","volume":"61","author":"Bernstein","year":"2012","journal-title":"Gut"},{"key":"2023112213075425700_CIT0003","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/ibd\/izy015","article-title":"Quality of life in inflammatory bowel disease: a systematic review and meta-analyses - part I.","volume":"24","author":"Knowles","year":"2018","journal-title":"Inflamm Bowel Dis."},{"key":"2023112213075425700_CIT0004","first-page":"2","article-title":"Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities.","volume":"85","author":"El-Gabalawy","year":"2010","journal-title":"J Rheumatol."},{"key":"2023112213075425700_CIT0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.12691\/ijcd-3-4-8","article-title":"The world incidence and prevalence of autoimmune diseases is increasing.","volume":"3","author":"Lerner","year":"2015","journal-title":"Int J Celiac Dis."},{"key":"2023112213075425700_CIT0006","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1016\/j.cgh.2019.03.040","article-title":"Incidence of immune-mediated inflammatory diseases among patients with inflammatory bowel diseases in Denmark.","volume":"17","author":"Burisch","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2023112213075425700_CIT0007","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/ibd\/izaa167","article-title":"Systematic review with meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease course of inflammatory bowel diseases.","volume":"27","author":"Attauabi","year":"2020","journal-title":"Inflamm Bowel Dis."},{"key":"2023112213075425700_CIT0008","doi-asserted-by":"crossref","first-page":"17562848211004840","DOI":"10.1177\/17562848211004839","article-title":"Systematic review and meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease localization and behavior of Crohn\u2019s disease.","volume":"14","author":"Attauabi","year":"2021","journal-title":"Ther Adv Gastroenterol."},{"key":"2023112213075425700_CIT0009","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrg3502","article-title":"Genetic insights into common pathways and complex relationships among immune-mediated diseases.","volume":"14","author":"Parkes","year":"2013","journal-title":"Nat Rev Genet."},{"key":"2023112213075425700_CIT0010","first-page":"2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting - meta-analysis of observational studies in epidemiology (MOOSE) group B.","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA Neurol."},{"key":"2023112213075425700_CIT0011","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both.","author":"Shea","year":"2017;358:4008","journal-title":"BMJ"},{"key":"2023112213075425700_CIT0012","doi-asserted-by":"crossref","DOI":"10.1186\/s13643-020-01542-z","article-title":"PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews.","author":"Rethlefsen","year":"2021;10:39","journal-title":"Syst Rev."},{"key":"2023112213075425700_CIT0013","author":"Ryan","year":"2016"},{"key":"2023112213075425700_CIT0014","author":"Wells"},{"key":"2023112213075425700_CIT0015","first-page":"312","article-title":"Primary sclerosing cholangitis in Turkish patients: characteristic features and prognosis.","volume":"8","author":"Ataseven","year":"2009","journal-title":"Hepatobiliary Pancreat Dis Int."},{"key":"2023112213075425700_CIT0016","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/003655202760373434","article-title":"Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.","volume":"37","author":"Boberg","year":"2002","journal-title":"Scand J Gastroenterol."},{"key":"2023112213075425700_CIT0017","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/MEG.0000000000000596","article-title":"Primary sclerosing cholangitis associated with inflammatory bowel disease: an observational study in a Southern Europe population focusing on new therapeutic options.","volume":"28","author":"Franceschet","year":"2016","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"2023112213075425700_CIT0018","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1097\/MEG.0b013e328331c2b7","article-title":"Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study.","volume":"22","author":"Garioud","year":"2010","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"2023112213075425700_CIT0019","first-page":"61","article-title":"Clinical course of primary sclerosing cholangitis and concomitant ulcerative colitis - a preliminary report of retrospective study among patients from Southern Poland.","volume":"55","author":"Glowacki","year":"2015","journal-title":"Folia Med Cracov."},{"key":"2023112213075425700_CIT0020","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/ajg.2016.55","article-title":"Duration of inflammatory bowel disease is associated with increased risk of cholangiocarcinoma in patients with primary sclerosing cholangitis and IBD.","volume":"111","author":"Gulamhusein","year":"2016","journal-title":"Am J Gastroenterol."},{"key":"2023112213075425700_CIT0021","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cgh.2011.09.015","article-title":"Lower incidence of biliary carcinoma in patients with primary sclerosing cholangitis and high serum levels of immunoglobulin E.","volume":"10","author":"Hirano","year":"2012","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2023112213075425700_CIT0022","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1440-1746.1990.tb01818.x","article-title":"Primary sclerosing cholangitis: clinical and immunopathological review of 21 cases.","volume":"5","author":"Jeffrey","year":"1990","journal-title":"J Gastroenterol Hepatol."},{"key":"2023112213075425700_CIT0023","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3109\/00365529709011222","article-title":"Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study.","volume":"32","author":"Kornfeld","year":"1997","journal-title":"Scand J Gastroenterol."},{"key":"2023112213075425700_CIT0024","doi-asserted-by":"crossref","first-page":"e0209352","DOI":"10.1371\/journal.pone.0209352","article-title":"Clinical characteristics and outcomes of primary sclerosing cholangitis and ulcerative colitis in Japanese patients.","volume":"13","author":"Kumagai","year":"2018","journal-title":"PLoS One."},{"key":"2023112213075425700_CIT0025","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00384-009-0773-4","article-title":"Primary sclerosing cholangitis: outcome of patients undergoing restorative proctocolecetomy for ulcerative colitis.","volume":"24","author":"Lepisto","year":"2009","journal-title":"Int J Colorectal Dis."},{"key":"2023112213075425700_CIT0026","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/PAS.0b013e3181bc96f9","article-title":"Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma.","volume":"34","author":"Lewis","year":"2010","journal-title":"Am J Surg Pathol."},{"key":"2023112213075425700_CIT0027","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S0016-5085(89)80078-2","article-title":"Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis.","volume":"96","author":"Cangemi","year":"1989","journal-title":"Gastroenterology"},{"key":"2023112213075425700_CIT0028","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/liv.13328","article-title":"Epidemiology and outcomes of primary sclerosing cholangitis with and without inflammatory bowel disease in an Australian cohort.","volume":"37","author":"Liu","year":"2017","journal-title":"Liver Int."},{"key":"2023112213075425700_CIT0029","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3109\/00365521.2014.946085","article-title":"Colorectal cancer and cholangiocarcinoma in patients with primary sclerosing cholangitis and inflammatory bowel disease.","volume":"50","author":"Manninen","year":"2015","journal-title":"Scand J Gastroenterol."},{"key":"2023112213075425700_CIT0030","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000658-199010000-00017","article-title":"Surgical aspects of sclerosing cholangitis. Results in 178 patients.","volume":"212","author":"Martin","year":"1990","journal-title":"Ann Surg."},{"key":"2023112213075425700_CIT0031","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1002\/lt.22320","article-title":"Pediatric liver transplantation for primary sclerosing cholangitis.","volume":"17","author":"Miloh","year":"2011","journal-title":"Liver Transplant."},{"key":"2023112213075425700_CIT0032","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1365-2036.2012.05063.x","article-title":"The impact of ulcerative colitis on the long-term outcome of patients with primary sclerosing cholangitis.","volume":"35","author":"Navaneethan","year":"2012","journal-title":"Aliment Pharmacol Ther."},{"key":"2023112213075425700_CIT0033","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1093\/gastro\/gov007","article-title":"Comparison of outcomes for patients with primary sclerosing cholangitis associated with ulcerative colitis and Crohn\u2019s disease.","volume":"4","author":"Navaneethan","year":"2016","journal-title":"Gastroenterol Rep."},{"key":"2023112213075425700_CIT0034","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s00384-018-3123-6","article-title":"Risk factors and clinical courses of concomitant primary sclerosing cholangitis and ulcerative colitis: a Korean multicenter study.","volume":"33","author":"Park","year":"2018","journal-title":"Int J Colorectal Dis."},{"key":"2023112213075425700_CIT0035","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jhep.2010.02.030","article-title":"In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival.","volume":"53","author":"Rudolph","year":"2010","journal-title":"J Hepatol."},{"key":"2023112213075425700_CIT0036","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/2050640617717156","article-title":"Impact of age at diagnosis on disease progression in patients with primary sclerosing cholangitis.","volume":"6","author":"Rupp","year":"2018","journal-title":"United Eur Gastroenterol J."},{"key":"2023112213075425700_CIT0037","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/apt.15375","article-title":"Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis.","volume":"50","author":"Ruhlemann","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"2023112213075425700_CIT0038","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/hep.510310103","article-title":"Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study.","volume":"31","author":"Chalasani","year":"2000","journal-title":"Hepatology"},{"key":"2023112213075425700_CIT0039","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/hep4.1276","article-title":"Frequency, risk factors, and outcome of gallbladder polyps in patients with primary sclerosing cholangitis: a case-control study.","volume":"2","author":"Torabi Sagvand","year":"2018","journal-title":"Hepatol Commun."},{"key":"2023112213075425700_CIT0040","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s00534-010-0319-8","article-title":"Clinical characteristics of inflammatory bowel disease associated with primary sclerosing cholangitis.","volume":"18","author":"Sano","year":"2011","journal-title":"J Hepatobiliary Pancreat Sci."},{"key":"2023112213075425700_CIT0041","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/00365528209181041","article-title":"Sclerosing cholangitis in ulcerative colitis. A follow-up study.","volume":"17","author":"Schrumpf","year":"1982","journal-title":"Scand J Gastroenterol."},{"key":"2023112213075425700_CIT0042","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.1478-3231.2008.01726.x","article-title":"Outcome and prognostic factors of 391 Japanese patients with primary sclerosing cholangitis.","volume":"28","author":"Tanaka","year":"2008","journal-title":"Liver Int."},{"key":"2023112213075425700_CIT0043","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4292\/wjgpt.v4.i3.61","article-title":"Outcome of patients with primary sclerosing cholangitis and ulcerative colitis undergoing colectomy.","volume":"4","author":"Treeprasertsuk","year":"2013","journal-title":"World J Gastrointest Pharmacol Ther."},{"key":"2023112213075425700_CIT0044","first-page":"1386","article-title":"-term outcomes of pediatric-onset primary sclerosing cholangitis: a single-center experience in Japan.","volume":"49","author":"Umetsu","year":"2019","journal-title":"Long"},{"key":"2023112213075425700_CIT0045","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/MPG.0000000000001368","article-title":"The natural history of primary sclerosing cholangitis in children: a large single-center longitudinal cohort study.","volume":"63","author":"Valentino","year":"2016","journal-title":"J Pediatr Gastroenterol Nutr."},{"key":"2023112213075425700_CIT0046","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1053\/j.gastro.2017.02.038","article-title":"Patient age, sex, and inflammatory bowel disease phenotype associate with course of primary sclerosing cholangitis.","volume":"152","author":"Weismuller","year":"2017","journal-title":"Gastroenterology"},{"key":"2023112213075425700_CIT0047","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/hep.1840100406","article-title":"Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis.","volume":"10","author":"Wiesner","year":"1989","journal-title":"Hepatology"},{"key":"2023112213075425700_CIT0048","first-page":"86","article-title":"Clinical outcomes and management of patients with concomitant primary sclerosing cholangitis and inflammatory bowel disease.","volume":"33","author":"Wu","year":"2018","journal-title":"J Gastroenterol Hepatol."},{"key":"2023112213075425700_CIT0049","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jhep.2008.08.013","article-title":"High lifetime risk of cancer in primary sclerosing cholangitis.","volume":"50","author":"Claessen","year":"2009","journal-title":"J Hepatol."},{"key":"2023112213075425700_CIT0050","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1093\/ecco-jcc\/jju013","article-title":"Prognosis of primary sclerosing cholangitis in israel is independent of coexisting inflammatory bowel Disease.","volume":"9","author":"Yanai","year":"2015","journal-title":"J Crohns Colitis."},{"key":"2023112213075425700_CIT0051","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/hep.21960","article-title":"Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis.","volume":"47","author":"Charatcharoenwitthaya","year":"2008","journal-title":"Hepatology"},{"key":"2023112213075425700_CIT0052","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00042737-200306000-00013","article-title":"Inflammatory bowel disease and liver transplantation for primary sclerosing cholangitis.","volume":"15","author":"van de Vrie","year":"2003","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"2023112213075425700_CIT0053","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1136\/gutjnl-2016-313681","article-title":"A novel prognostic model for transplant-free survival in primary sclerosing cholangitis.","volume":"67","author":"De Vries","year":"2018","journal-title":"Gut"},{"key":"2023112213075425700_CIT0054","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/hep.29204","article-title":"The natural history of primary sclerosing cholangitis in 781 children: a multicenter, international collaboration.","volume":"66","author":"Deneau","year":"2017","journal-title":"Hepatology"},{"key":"2023112213075425700_CIT0055","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/apt.13516","article-title":"Patients with large-duct primary sclerosing cholangitis and Crohn\u2019s disease have a better outcome than those with ulcerative colitis, or without IBD.","volume":"43","author":"Fevery","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"key":"2023112213075425700_CIT0056","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/MEG.0000000000000747","article-title":"Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort Study: prevalence, risk factors, and long-term follow-up.","volume":"29","author":"Fraga","year":"2017","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"2023112213075425700_CIT0057","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/rheumatology\/keu388","article-title":"Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS.","volume":"54","author":"Essers","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2023112213075425700_CIT0058","first-page":"214","article-title":"Do extra-articular manifestations influence outcome in ankylosing spondylitis? 12-year results from OASIS.","volume":"34","author":"Essers","year":"2016","journal-title":"Clin Exp Rheumatol."},{"key":"2023112213075425700_CIT0059","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.3899\/jrheum.101049","article-title":"Differential features between primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease.","volume":"38","author":"Perez Alamino","year":"2011","journal-title":"J Rheumatol."},{"key":"2023112213075425700_CIT0060","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3899\/jrheum.181326","article-title":"Effect of gut involvement in patients with high probability of early spondyloarthritis: data from the DESIR cohort.","volume":"47","author":"Wendling","year":"2019","journal-title":"J Rheumatol."},{"key":"2023112213075425700_CIT0061","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/gut.11.9.748","article-title":"Arthropathy, ankylosing spondylitis, and clubbing of fingers in ulcerative colitis.","volume":"11","author":"Jalan","year":"1970","journal-title":"Gut"},{"key":"2023112213075425700_CIT0062","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1007\/s10067-018-4290-0","article-title":"The effect of extra-articular manifestations on tumor necrosis factor-alpha inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.","volume":"37","author":"Kim","year":"2018","journal-title":"Clin Rheumatol."},{"key":"2023112213075425700_CIT0063","doi-asserted-by":"crossref","first-page":"e5652","DOI":"10.1097\/MD.0000000000005652","article-title":"Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort.","volume":"95","author":"Landi","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2023112213075425700_CIT0064","doi-asserted-by":"crossref","first-page":"e4267","DOI":"10.1097\/MD.0000000000004267","article-title":"Clinical features of Crohn disease concomitant with ankylosing spondylitis: a preliminary single-center study.","volume":"95","author":"Liu","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2023112213075425700_CIT0065","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4081\/reumatismo.2014.756","article-title":"Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFalpha drugs.","volume":"66","author":"Perrotta","year":"2014","journal-title":"Reumatismo"},{"key":"2023112213075425700_CIT0066","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/ard.2008.100503","article-title":"Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study.","volume":"68","author":"Vosse","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"2023112213075425700_CIT0067","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s10067-016-3374-y","article-title":"Gastrointestinal comorbidities in patients with psoriatic arthritis.","volume":"35","author":"Zohar","year":"2016","journal-title":"Clin Rheumatol."},{"key":"2023112213075425700_CIT0068","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/art.40551","article-title":"Association of inflammatory bowel disease and acute anterior uveitis, but not psoriasis, with disease duration in patients with axial spondyloarthritis: results from two Belgian nationwide axial spondyloarthritis cohorts.","volume":"70","author":"Varkas","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"2023112213075425700_CIT0069","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1468-3083.2011.04153.x","article-title":"Associated comorbidities in psoriasis and inflammatory bowel disease.","volume":"26","author":"Binus","year":"2012","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"2023112213075425700_CIT0070","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1097\/MIB.0000000000001169","article-title":"Prevalence and phenotype of concurrent psoriasis and inflammatory bowel disease.","volume":"23","author":"Eppinga","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"2023112213075425700_CIT0071","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/ijdvl.IJDVL_875_17","article-title":"Psoriasis increases the risk of concurrent inflammatory bowel disease: a population-based nationwide study in Korea.","volume":"85","author":"Lee","year":"2019","journal-title":"Indian J Dermatol Venereol Leprol."},{"key":"2023112213075425700_CIT0072","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1093\/ecco-jcc\/jjv068","article-title":"Psoriasis phenotype in inflammatory bowel disease: a case-control prospective study.","volume":"9","author":"Lolli","year":"2015","journal-title":"J Crohns Colitis."},{"key":"2023112213075425700_CIT0073","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/1346-8138.14900","article-title":"Prevalence of inflammatory bowel disease in Japanese psoriatic patients.","volume":"46","author":"Masaki","year":"2019","journal-title":"J Dermatol."},{"key":"2023112213075425700_CIT0074","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/jdv.12305","article-title":"Psoriasis concurrent with inflammatory bowel disease.","volume":"28","author":"Park","year":"2014","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"2023112213075425700_CIT0075","doi-asserted-by":"crossref","first-page":"e414","DOI":"10.1111\/jdv.14230","article-title":"Clinical characteristics of psoriasis in inflammatory bowel disease patients.","volume":"31","author":"Pescitelli","year":"2017","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"2023112213075425700_CIT0076","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ad.2014.06.003","article-title":"Immune-mediated inflammatory diseases and other comorbidities in patients with psoriasis: baseline characteristics of patients in the AQUILES study.","volume":"106","author":"Vanaclocha","year":"2015","journal-title":"Actas Dermosifiliogr."},{"key":"2023112213075425700_CIT0077","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1136\/gut.2005.074815","article-title":"Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial.","volume":"55","author":"Brooklyn","year":"2006","journal-title":"Gut"},{"key":"2023112213075425700_CIT0078","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.4103\/0366-6999.218004","article-title":"Comparison of clinical features between pyoderma gangrenosum concomitant by inflammatory bowel disease and idiopathic pyoderma gangrenosum.","volume":"130","author":"Jiang","year":"2017","journal-title":"Chin Med J (Engl)."},{"key":"2023112213075425700_CIT0079","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/00004836-198306000-00002","article-title":"Does intestinal resection heal the pyoderma gangrenosum of inflammatory bowel disease?","volume":"5","author":"Talansky","year":"1983","journal-title":"J Clin Gastroenterol."},{"key":"2023112213075425700_CIT0080","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2310\/7750.2014.14053","article-title":"Pyoderma gangrenosum among patients with inflammatory bowel disease: a descriptive cohort study.","volume":"18","author":"Weizman","year":"2015","journal-title":"J Cutan Med Surg."},{"key":"2023112213075425700_CIT0081","first-page":"S50","article-title":"Concurrrence of multiple sclerosis and inflammatory bowel disease in general population: frequency, phenotypes and clinical course.","volume":"15","author":"Buzaglo","year":"2009","journal-title":"Mult Scler."},{"key":"2023112213075425700_CIT0082","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1177\/1352458513515081","article-title":"Milder multiple sclerosis course in patients with concomitant inflammatory bowel disease.","volume":"20","author":"Zephir","year":"2014","journal-title":"Mult Scler."},{"key":"2023112213075425700_CIT0083","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/jdv.15904","article-title":"Burden, predictors and temporal relationships of comorbidities in patients with hidradenitis suppurativa: a hospital-based cohort study.","volume":"34","author":"Jorgensen","year":"2019","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"2023112213075425700_CIT0084","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1002\/ibd.20898","article-title":"Inflammatory bowel disease in the setting of autoimmune pancreatitis.","volume":"15","author":"Ravi","year":"2009","journal-title":"Inflamm Bowel Dis."},{"key":"2023112213075425700_CIT0085","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/0168-8278(92)90178-R","article-title":"Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis.","volume":"14","author":"Perdigoto","year":"1992","journal-title":"J Hepatol."},{"key":"2023112213075425700_CIT0086","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1365-2222.2005.02358.x","article-title":"A case-control study of bronchial asthma associated with ulcerative colitis: role of airway microvascular permeability.","volume":"35","author":"Kanazawa","year":"2005","journal-title":"Clin Exp Allergy."},{"key":"2023112213075425700_CIT0087","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1136\/gutjnl-2018-318074","article-title":"Epidemiology and implications of concurrent diagnosis of eosinophilic oesophagitis and IBD based on a prospective population-based analysis.","volume":"68","author":"Limketkai","year":"2019","journal-title":"Gut"},{"key":"2023112213075425700_CIT0088","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/j.1572-0241.2007.01215.x","article-title":"Clustering of inflammatory bowel disease with immune mediated diseases among members of a Northern California-managed care organization.","volume":"102","author":"Weng","year":"2007","journal-title":"Am J Gastroenterol."},{"key":"2023112213075425700_CIT0089","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nrg2489","article-title":"Detecting shared pathogenesis from the shared genetics of immune-related diseases.","volume":"10","author":"Zhernakova","year":"2009","journal-title":"Nat Rev Genet."},{"key":"2023112213075425700_CIT0090","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0140-6736(96)90734-5","article-title":"Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease.","volume":"347","author":"Satsangi","year":"1996","journal-title":"Lancet"},{"key":"2023112213075425700_CIT0091","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/MEG.0000000000000004","article-title":"IL23R polymorphisms influence phenotype and response to therapy in patients with ulcerative colitis.","volume":"26","author":"Cravo","year":"2014","journal-title":"Eur J Gastroenterol Hepatol."},{"key":"2023112213075425700_CIT0092","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1053\/j.gastro.2014.02.009","article-title":"The microbiome in inflammatory bowel disease: current status and the future ahead.","volume":"146","author":"Kostic","year":"2014","journal-title":"Gastroenterology"},{"key":"2023112213075425700_CIT0093","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/gutjnl-2015-310500","article-title":"The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls.","volume":"66","author":"Kummen","year":"2017","journal-title":"Gut"},{"key":"2023112213075425700_CIT0094","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/BOR.0000000000000187","article-title":"The intestinal microbiome in spondyloarthritis.","volume":"27","author":"Gill","year":"2015","journal-title":"Curr Opin Rheumatol."},{"key":"2023112213075425700_CIT0095","doi-asserted-by":"crossref","first-page":"463","DOI":"10.3390\/pathogens9060463","article-title":"Gut microbiome in psoriasis: an updated review.","volume":"9","author":"Sikora","year":"2020","journal-title":"Pathogens"},{"key":"2023112213075425700_CIT0096","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjaa260","article-title":"Ustekinumab for extra-intestinal manifestations of inflammatory bowel disease: a systematic literature review.","author":"Guillo","year":"2021;15:1236-1243","journal-title":"J Crohns Colitis."},{"key":"2023112213075425700_CIT0097","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1).","author":"Leonardi","year":"2008;371:1665-1674","journal-title":"Lancet"},{"key":"2023112213075425700_CIT0098","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.15148","article-title":"Systematic review with meta-analysis: risk factors for recurrent primary sclerosing cholangitis after liver transplantation.","volume":"49","author":"Steenstraten","year":"2019","journal-title":"Aliment Pharmacol Ther."},{"key":"2023112213075425700_CIT0099","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/s-2008-1040420","article-title":"Relationship of inflammatory bowel disease and primary sclerosing cholangitis.","volume":"11","author":"Fausa","year":"1991","journal-title":"Semin Liver Dis."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izac003\/42387225\/izac003.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/28\/11\/1756\/53683052\/izac003.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/28\/11\/1756\/53683052\/izac003.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T17:40:01Z","timestamp":1700674801000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/28\/11\/1756\/6522052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,4]]},"references-count":99,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,2,4]]},"published-print":{"date-parts":[[2022,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izac003","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,2,4]]}}}